Under the agreement, Glenmark has received exclusive rights to develop and commercialise Aumolertinib across its licensed territories, which include the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and a few selected Caribbean countries covered by the agreement. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,962.00, down by ₹23.60, or 1.19%, on the BSE.
